MBP-8298, a synthetic peptide analog of myelin basic protein for the treatment of multiple sclerosis

Current Opinion in Molecular Therapeutics

Volumn 9, Issue 4, 2007, Pages 398-402

  Darlington, Cynthia ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

MBP 8298; MYELIN BASIC PROTEIN; SYNTHETIC PEPTIDE; UNCLASSIFIED DRUG;

BLOOD PRESSURE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; FLUSHING; HUMAN; IMMUNOMODULATION; INJECTION SITE REACTION; MULTIPLE SCLEROSIS; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

ANIMALS; DRUG DESIGN; HUMANS; MULTIPLE SCLEROSIS; MYELIN BASIC PROTEINS; PATENTS AS TOPIC; PEPTIDE FRAGMENTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 34547914800     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (32)

1. 246587 Briana announces collaboration on multiple sclerosis clinical development program. Briana Bio-Tech Inc PRESS RELEASE 1997 May 15
2. 265633 Briana licenses multiple sclerosis technology. Briana Bio-Tech Inc PRESS RELEASE 1997 October 09
3. 430009 Drug development pipeline: [MBP-8298]. BioMS Medical COMPANY COMMUNICATION 2001 November 09
4. 430016 About MBP-8298. BioMS Medical COMPANY WORLD WIDE WEB SITE 2001 November 21
5. 452889 BioMS Medical announces patents for MBP-8298. BioMS Medical Corp PRESS RELEASE 2002 May 28
6. 472840 BioMS Medical reports progress on partnering initiative for lead MS product. BioMS Medical Corp PRESS RELEASE 2002 December 04
7. 500288 AutoImmune Inc reports 2003 second quarter financial results. AutoImmune Inc PRESS RELEASE 2003 August 07
8. 575087 BioMS initiates MBP-8298 phase II/III multiple sclerosis trial. BioMS Medical Corp PRESS RELEASE 2004 December 08
9. 613632 BioMS Medical commences UK patient enrollment in multiple sclerosis trial. BioMS Medical Corp PRESS RELEASE 2005 July 21
10. 631054 Data safety monitoring board gives positive review for BioMS Medical's pivotal MS trial. BioMS Medical Corp PRESS RELEASE 2005 October 27
11. 650693 BioMS secures manufacturing contracts for late-stage MS therapy. BioMS Medical Corp PRESS RELEASE 2006 February 15
12. 667888 BioMS gets go-ahead for phase II relapsing-remitting MS trial. BioMS Medical Corp PRESS RELEASE 2006 May 16
13. 673600 Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA class II-defined cohort of patients with progressive multiple sclerosis: Results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Warren KG, Catz I, Ferenczi LZ, Krantzb MJ EUR J NEUROL 2006 13 8 887-895
14. 675339 BioMS Medical expands pivotal multiple sclerosis trial into the Netherlands. BioMS Medical Corp PRESS RELEASE 2006
15. 681193 Form 10-K. AutoImmune Inc FORM 10-K 2006 March 23
16. 684107 BioMS Medical announces second quarter 2006 results. BioMS Medical Corp PRESS RELEASE 2006 August 14
17. 689164 BioMS Medical expands pivotal multiple sclerosis trial into Spain and Germany. PRESS RELEASE 2006 September 07
18. 730861 BioMS Medical expands pivotal multiple sclerosis trial into Finland. BioMS Medical Corp PRESS RELEASE 2006 October 12
19. 772331 Kinetic profiles of cerebrospinal fluid anti-MBP in response to intravenous MBP synthetic peptide DENP(85)VVHFFKNIVTP(96)RT in multiple sclerosis patients. Warren KG, Catz I MULT SCLER 2000 6 5 300-311
20. 795110 Natalizumab update. Sweet BV AM J HEALTH-SYSTEM PHARM 2007 64 7 705-716
21. 799196 An extensive search for autoantibodies to myelin basic protein in cerebrospinal fluid of non-multiple-sclerosis patients: Implications for the pathogenesis of multiple sclerosis. Warren KG, Catz I EUR NEUROL 1999 42 2 95-104
22. 799197 Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis. Warren KG, Catz I, Wucherpfennig KW J NEUROL SCI 1997 152 1 31-38
23. 799198 Autoantibodies to myelin basic protein within multiple sclerosis central nervous system tissue. Warren KG, Catz I J NEUROL SCI 1993 115 2 169-176
24. 799199 Increased synthetic peptide specificity of tissue-CSF bound anti-MBP in multiple sclerosis. Warren KG, Catz I J NEUROIMMUNOL 1993 43 1-2 87-96
25. 799200 Optic neuritis anti-myelin basic protein synthetic peptide specificity. Warren KG, Catz I, Shutt K J NEUROL SCI 1992 109 1 88-95
26. 799201 Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid. Warren KG, Catz I J NEUROIMMUNOL 1992 39 1-2 81-89
27. 799217 Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: The minimal B-cell epitope and a model of its features. Warren KG, Catz I, Steinman L PROC NATL ACAD SCI USA 1995 92 24 11061-11065
28. 801850 MBP-8298: Product information. BioMS Medical Corp COMPANY WORLD WIDE WEB SITE 2007 June 05
29. 802225 BioMS Medical initiates enrollment in pivotal US phase III multiple sclerosis trial. BioMS Medical Corp PRESS RELEASE 2007 June 05
30. 805390 Glatiramer acetate: Mechanisms of action in multiple sclerosis. Ziemssen T, Schrempf W INT REV NEUROBIOL 2007 79 537-570
31. 805580 Secondary progressive multiple sclerosis: Current knowledge and future challenges. Rovaris M, Confavreux C, Furlan R, Kappos L, Comi G, Filippi M LANCET NEUROLOGY 2006 5 4 343-354
32. 805622 NCT00468611: Efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis (MAESTRO-03). BioMS Medical Corp CLINICALTRIALS.GOV 2007 June 14